Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) traded up 0.1% on Monday . The stock traded as high as $7.07 and last traded at $6.98. 450,942 shares traded hands during mid-day trading, an increase of 60% from the average session volume of 280,981 shares. The stock had previously closed at $6.97.
Shionogi & Co., Ltd. Stock Performance
The company's 50-day moving average price is $6.98 and its two-hundred day moving average price is $8.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.37 and a current ratio of 5.86. The stock has a market cap of $11.91 billion, a PE ratio of 11.93, a PEG ratio of 4.76 and a beta of 0.21.
Shionogi & Co., Ltd. Company Profile
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Further Reading
Before you consider Shionogi & Co., Ltd., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. wasn't on the list.
While Shionogi & Co., Ltd. currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
